Stockscreener 앱 받기
8.77
1.68%
-0.15
시간 외 거래:
8.77
전일 마감가:
$8.92
열려 있는:
$8.9
하루 거래량:
1.70M
Relative Volume:
1.87
시가총액:
$460.60M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.5942
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-20.35%
1개월 성능:
-23.14%
6개월 성능:
+14.94%
1년 성능:
+37.25%
1일 변동 폭
$8.665
$9.025
1주일 범위
$7.81
$11.46
52주 변동 폭
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.77 | 468.48M | 1.02B | -757.20M | -257.90M | -14.76 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
EBS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Emergent BioSolutions (EBS) SVP reports 116-share tax-withholding disposition - Stock Titan
Emergent BioSolutions (EBS) CFO logs 683-share tax-withholding disposition - Stock Titan
Emergent BioSolutions (EBS) EVP has 313 shares withheld for RSU taxes - Stock Titan
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - The Globe and Mail
Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors - marketscreener.com
Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts - TipRanks
Emergent BioSolutions appoints John D. Fowler, Jr. as director and Audit and Finance Committee member - TradingView
John Fowler joins Emergent BioSolutions (NYSE: EBS) board, Audit role - Stock Titan
Emergent Biosolutions Announces Appointment Of John D. Fowler, Jr. To Board Of Directors - TradingView
Former Wells Fargo banker John Fowler joins Emergent BioSolutions board - Stock Titan
Emergent Biosolutions secures new contracts with Public Health Agency of Canada and Defence Department - Traders Union
Aug Levels: Is Emergent BioSolutions Inc stock showing strong momentumPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Earnings: Revenue, Margins And GAAP Losses Paint Mixed Picture (EBS) - Seeking Alpha
Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy - MarketBeat
Emergent Biosolutions Q4 Earnings Call Highlights - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Emergent BioSolutions (EBS) Stock Falls on Disappointing Revenue Guidance - GuruFocus
Emergent BioSolutions authorizes $50M stock buyback program By Investing.com - Investing.com India
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 21.62% Potential Upside Amidst Challenging Revenue Growth - DirectorsTalk Interviews
Emergent BioSolutions Stock Pre-Market (-21%): Q4 Revenue Miss & Weak NARCAN Sales - Trefis
Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges - GuruFocus
Emergent BioSolutions Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:EBS) 2026-02-26 - Seeking Alpha
Emergent Biosolutions: Q4 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Emergent Biosolutions Misses Q4 2025 Expectations, Stock Edges Up - Investing.com
Emergent BioSolutions (EBS) Projects Significant Growth in FY26 Earnings - GuruFocus
Emergent BioSolutions (EBS) Eyes Global Expansion and Growth Ini - GuruFocus
Emergent BioSolutions Q4 2025 slides: transformation advances despite revenue miss - Investing.com
Emergent BioSolutions secures $140M contracts with Canada - Investing.com Canada
Emergent BioSolutions Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Emergent BioSolutions (EBS) Secures Major Contracts with Canada - GuruFocus
Emergent BioSolutions (EBS) Reports Q4 Revenue Miss Amid Product - GuruFocus
Emergent BioSolutions (EBS) Approves $50M Stock Repurchase Plan - GuruFocus
Emergent BioSolutions (NYSE: EBS) outlines 2025 turnaround strategy - Stock Titan
Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results - MarketBeat
Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround - TipRanks
Emergent BioSolutions authorizes $50M stock buyback program - Investing.com
Earnings Summary: Emergent BioSolutions Q4 - Benzinga
Emergent BioSolutions (NYSE: EBS) swings from 2024 loss to 2025 profit - Stock Titan
Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. - marketscreener.com
Emergent BioSolutions Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness - Yahoo Finance
Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ... By GuruFocus - Investing.com Canada
Emergent Biosolutions: Fourth Quarter Financial Overview - Bitget
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program - Bitget
Three AI Analyst Stocks, LSBK, EBS, and MNSO, Projected to Rise Over 20% - Intellectia AI
How dovish Fed policy supports Emergent BioSolutions Inc. (ER4) stock2025 Trading Volume Trends & Stock Portfolio Risk Management - mfd.ru
Emergent BioSolutions Inc. (EBS) Stock Analysis: Navigating a 22.84% Potential Upside Amidst Healthcare Challenges - DirectorsTalk Interviews
NY Attorney General Brings Action Against Former Emergent BioSolutions CEO - marketscreener.com
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
1.85%
자본화:
|
볼륨(24시간):